Niagen Bioscience, Inc.
NAGE
$6.53
-$0.23-3.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 273.15% | 122.95% | 79.19% | 67.03% | 70.15% |
| Total Depreciation and Amortization | -12.96% | -16.12% | -11.58% | -6.76% | -9.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -118.30% | -32.98% | -22.52% | -6.32% | -1.50% |
| Change in Net Operating Assets | -31.30% | -161.01% | -647.99% | 172.82% | 172.21% |
| Cash from Operations | 70.14% | -32.00% | -46.31% | 190.45% | 147.14% |
| Capital Expenditure | -10.14% | 61.54% | 69.23% | 75.50% | 55.69% |
| Sale of Property, Plant, and Equipment | 300.00% | 300.00% | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | 67.69% | 68.75% | 76.75% | 57.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 26.67% | 50.00% | 55.00% | -21.43% | 6.25% |
| Issuance of Common Stock | -- | -78.82% | -92.28% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 30.67% | -38.71% | -11.69% | -11.69% | 2.60% |
| Cash from Financing | 6,065.56% | -79.84% | -93.42% | -101.35% | -101.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 151.82% | -58.37% | -84.15% | 105.96% | 188.51% |